BioCentury
ARTICLE | Clinical News

Firazyr icatibant regulatory update

August 29, 2011 7:00 AM UTC

FDA approved Firazyr icatibant from Shire to treat acute attacks of hereditary angioedema (HAE) in adults. The company said Firazyr is the first self-administered subcutaneous treatment approved in the U.S. for acute HAE. Shire launched the product with a wholesale acquisition cost of $6,800 per dose. Shire said that while most patients respond to a single dose of Firazyr, up to 2 additional doses may be administered within a 24 hour period, if response is inadequate or symptoms recur. Firazyr, a selective peptidomimetic bradykinin B2 receptor ( BDKRB2; B2R) antagonist, is supplied in a room temperature-stable, prefilled syringe. ...